VolitionRx (NYSE:VNRX) Earns Buy Rating from D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $5.00 target price on the stock.

A number of other equities analysts also recently issued reports on the company. StockNews.com initiated coverage on VolitionRx in a research report on Friday, January 31st. They set a “sell” rating on the stock. Benchmark reissued a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Trading Down 3.2 %

VNRX opened at $0.60 on Thursday. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.22. The business’s fifty day simple moving average is $0.62 and its 200-day simple moving average is $0.65. The company has a market capitalization of $55.60 million, a price-to-earnings ratio of -1.67 and a beta of 1.20.

Insider Activity at VolitionRx

In related news, CEO Cameron John Reynolds acquired 139,811 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average price of $0.57 per share, with a total value of $79,692.27. Following the completion of the transaction, the chief executive officer now directly owns 2,117,404 shares in the company, valued at $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the purchase, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. The trade was a 39.51 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 358,266 shares of company stock valued at $204,212 over the last quarter. 12.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC raised its holdings in VolitionRx Limited (NYSE:VNRX) by 15.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.